top of page

Highly accurate.
Highly affordable.
Highly accessible.

A non-invasive, blood-based test for multi-cancer early detection


Our technology can save lives with early cancer detection

Cancer is one of the most common causes of death in the US, second only to cardiovascular diseases. Multi-cancer early detection is on the cutting edge of cancer research, promising to reduce cancer deaths by 40%.

Non-invasive multi-cancer early detection

miRoncol is developing a novel test, using well-established technology and infrastructure, that can detect multiple types of cancer in their early stages.

High accuracy

Compared to other multi-cancer early detection technologies, miRoncol's unique test demonstrates superior performance with high sensitivity and specificity.

High affordability

miRoncol provides a low-cost solution to cancer screening using an RT-PCR based assay of limited number of microRNAs.

High accessibility

miRoncol's test requires only a small blood sample, one that can be readily tested in any diagnostic lab across the US.


Scientifically-proven performance 


types of cancer are currently supported, with more on the way.


Specificity, i.e. <1% of non-cancer samples would be tested as positive.


Sensitivity, i.e. ~90% of actual cancer cases can be detected.


blood samples used for model development and validation.



A peer-reviewed publication.

At the 2021 World Conference on Lung Cancer, our study was not only selected for oral presentation, but also highlighted in the Meeting News.

Poster presentation at the 2022 Annual Meeting of American Association for Cancer Research.

Poster presentation at 2022 Annual Meeting of American Society of Clinical Oncology.

Be a part of the effort to save more lives from cancer!

Cancer touches all of us.


You can help make a change.

bottom of page